Received: from westeu11-emailsignatures-cloud.codetwo.com (20.93.157.195) by MI3PEPF00008492.mail.protection.outlook.com (10.167.240.153) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.360.3 via Frontend Transport; Thu, 27 Aug 2026 13:17:57 +0000 Received: from MI3PEPF00008492.eurprd03.prod.outlook.com (2603:10a6:102:53:cafe::39) by PR3P189CA0034.outlook.office365.com (2603:10a6:102:53::9) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.21.360.10 via Frontend Transport; Thu, 27 Aug 2026 13:17:57 +0000 Received: from AS8PR07CU003.outbound.protection.outlook.com (40.93.65.48) by westeu11-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Thu, 27 Aug 2026 13:17:56 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%4]) with mapi id 15.21.0360.008; Thu, 27 Aug 2026 13:17:53 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by VI1PR02MB10442.eurprd02.prod.outlook.com (2603:10a6:800:1cd::5) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.339.12; Thu, 27 Aug 2026 13:17:53 +0000 Received: from PAWPR02MB9997.eurprd02.prod.outlook.com (2603:10a6:102:2e6::19) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Thu, 27 Aug 2026 13:18:00 +0000 Received: from PR3P189CA0034.EURP189.PROD.OUTLOOK.COM (2603:10a6:102:53::9) by PAWPR02MB9997.eurprd02.prod.outlook.com (2603:10a6:102:2e6::19) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.360.10; Thu, 27 Aug 2026 13:17:58 +0000 From: "Kommunikatsioon - RA" To: =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: In-Reply-To: Subject: =?utf-8?Q?Ed:_K=C3=BCsimused_seoses_doonorluseg?= =?utf-8?Q?a?= Date: Thu, 27 Aug 2026 16:17:53 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0268_01DD4047.4A560530" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQKIK49lZm7YbCpa3c1usM2KMdwhuQIr43sBASjxV4cB07yC7w== Authentication-Results: spf=pass (sender IP is 20.93.157.195) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=pass action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|VI1PR02MB10442:EE_|MI3PEPF00008492:EE_|PAWPR02MB9997:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: f9273ff8-0714-4828-6c16-08df043d9c65 X-MS-Exchange-AtpMessageProperties: SA X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|366016|31052699007|23010399003|39142699007|10067099003|56012099006|11063799006|4143699003|8096899003|22082099003|18002099003|55112099003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(366016)(31052699007)(23010399003)(39142699007)(10067099003)(56012099006)(11063799006)(4143699003)(8096899003)(22082099003)(18002099003)(55112099003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: 1aM1aSUpnbOnnanjeNUUxbwFehj6OqtW4rQsNvgf5OpT4J15+PDOFj19HWtUE9MpHsQtrs596GF53FO0RA7DUWAZKMcnsPN2ZwKJpxZBA1fQP/MSFvRr+YCTNl6OUGv0NexLMRCZs053IHKo8nXk2fJDqqrsF6oZoobeUbJFJc7VJHDWB84rgf6eY0YFhyrsC0hLA63xAInbfmQqQc1KJ5s6ehd6h27WF56ebyPrQ2z9IOSpNgQ10FL0ScUhW/Y8N8lHiYBv6em8vQft45ua+y7pd2eadILjL966OP0N82zUW3S4hKgEOrvF1LyQqx+BZIKV5GmAdMNG0RIwesPFUA== X-MS-Exchange-Transport-CrossTenantHeadersStamped: PAWPR02MB9997 X-MS-Exchange-Transport-CrossTenantHeadersStamped: VI1PR02MB10442 X-CodeTwo-MessageID: 30c39c10-caf0-4094-bd08-5224726224be.20260827131756@westeu11-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-EOPAttributedMessage: 0 X-MS-Exchange-Transport-CrossTenantHeadersStripped: MI3PEPF00008492.eurprd03.prod.outlook.com X-MS-Office365-Filtering-Correlation-Id-Prvs: 4b972532-fc83-43b8-8387-08df043d99e7 X-MS-Exchange-Organization-ExpirationStartTime: 27 Aug 2026 13:17:57.3308 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: f9273ff8-0714-4828-6c16-08df043d9c65 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|31052699007|39142699007|82310400026|23010399003|35042699022|366016|10067099003|56012099006|11063799006|4143699003|8096899003|18002099003|22082099003|55112099003|41050700001; X-Forefront-Antispam-Report: CIP:20.93.157.195;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu11-emailsignatures-cloud.codetwo.com;PTR:westeu11-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(31052699007)(39142699007)(82310400026)(23010399003)(35042699022)(366016)(10067099003)(56012099006)(11063799006)(4143699003)(8096899003)(18002099003)(22082099003)(55112099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 27 Aug 2026 13:17:57.2640 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: f9273ff8-0714-4828-6c16-08df043d9c65 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.4403487 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0360.006 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et acceptlanguage: et-EE, en-US x-ms-exchange-organization-originalclientipaddress: 45.156.32.33 x-ms-exchange-organization-originalserveripaddress: 10.167.240.153 received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 20.93.157.195 as permitted sender) receiver=protection.outlook.com; client-ip=20.93.157.195; helo=westeu11-emailsignatures-cloud.codetwo.com; pr=C X-OlkEid: 00000000B02CA1B0966F474A8EB1ED1092032AA5070034AD76187591974DBF6C4F76951C873A01000200000000000C9DC03918ACEF4596C0CB2D860A15F300000000142200003D0963288808B940AD85A16D1445AD61 X-MS-Exchange-Organization-AuthMechanism: 04 msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-08-27T13:17:52.450Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; X-OrganizationHeadersPreserved: VI1PR02MB10442.eurprd02.prod.outlook.com X-CrossPremisesHeadersPromoted: MI3PEPF00008492.eurprd03.prod.outlook.com X-CrossPremisesHeadersFiltered: MI3PEPF00008492.eurprd03.prod.outlook.com X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[20.93.157.195];Helo=[westeu11-emailsignatures-cloud.codetwo.com] authentication-results-original: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; This is a multipart message in MIME format. ------=_NextPart_000_0268_01DD4047.4A560530 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit _____ Saatja: Merilin Lutsar Saadetud: neljapäev, 27. august 2026 13:27 Adressaat: Carmen Katariina Sikk - RA Teema: Küsimused seoses doonorlusega Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere, Carmen 🙂 Kirjutan Õhtulehest seoses munarakudoonorite värbamise ja selleks tehtavate reklaamidega. * Millised nõuded kehtivad Eestis munarakudoonorite värbamisele ja selleks tehtavatele reklaamidele? Kes teeb neile järelevalvet? * Kas kliinik võib reklaamis otsida konkreetsete omadustega doonorit, näiteks kindlas vanuses ning kindla juukse- või silmavärviga naist? Kas kui täpselt võib soovitud doonori omadusi määratleda, on seatud piiranguid? * Reklaamides tuuakse sageli selgelt välja doonorile makstav rahaline hüvitis ja võimalus teha teisele inimesele head. Millised nõuded kehtivad doonorluse eest makstava hüvitise reklaamimisele? * Kas munarakudoonorluse reklaamis peab olema välja toodud, et doonor peab läbima hormonaalse stimulatsiooni ja munarakkude kogumise protseduuri ning et sellega võivad kaasneda terviseriskid? * Kas reklaam võib olla eksitav või muul viisil probleemne, kui selles rõhutatakse näiteks kuni 1200-eurost hüvitist ja võimalust teha head, kuid ei mainita protseduuri olemust ega võimalikke terviseriske? * Kes kontrollib, et naine oleks enne nõusoleku andmist saanud piisavalt teavet? * Kas Ravimiametile on viimastel aastatel laekunud kaebusi või vihjeid munarakudoonorite värbamise või selleks tehtud reklaamide kohta? Kas järelevalve käigus on tuvastatud rikkumisi? Kui jah, siis milliseid? Lugupidamisega Merilin Lutsar ------=_NextPart_000_0268_01DD4047.4A560530 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

Saatja: Merilin Lutsar <merilin.lutsar@ohtuleht.ee>
Saadetud: neljap=C3=A4ev, 27. august 2026 13:27
Adressaat: Carmen Katariina Sikk - RA = <carmen.katariina.sikk@ravimiamet.ee>
Teema: K=C3=BCsimused seoses doonorlusega
 

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Tere, Carmen =F0=9F=99=82
Kirjutan =C3=95htulehest seoses munarakudoonorite v=C3=A4rbamise ja = selleks tehtavate reklaamidega.
  • Millised = n=C3=B5uded kehtivad Eestis munarakudoonorite v=C3=A4rbamisele ja = selleks tehtavatele reklaamidele? Kes teeb neile = j=C3=A4relevalvet?
  • Kas kliinik = v=C3=B5ib reklaamis otsida konkreetsete omadustega doonorit, = n=C3=A4iteks kindlas vanuses ning kindla juukse- v=C3=B5i = silmav=C3=A4rviga naist? Kas kui t=C3=A4pselt v=C3=B5ib soovitud doonori = omadusi m=C3=A4=C3=A4ratleda, on seatud piiranguid?
  • Reklaamides tuuakse = sageli selgelt v=C3=A4lja doonorile makstav rahaline h=C3=BCvitis ja = v=C3=B5imalus teha teisele inimesele head. Millised n=C3=B5uded kehtivad = doonorluse eest makstava h=C3=BCvitise reklaamimisele?
  • Kas munarakudoonorluse reklaamis peab olema v=C3=A4lja toodud, et doonor = peab l=C3=A4bima hormonaalse stimulatsiooni ja munarakkude kogumise = protseduuri ning et sellega v=C3=B5ivad kaasneda terviseriskid?
  • Kas reklaam v=C3=B5ib olla eksitav v=C3=B5i muul viisil probleemne, kui = selles r=C3=B5hutatakse n=C3=A4iteks kuni 1200-eurost h=C3=BCvitist ja = v=C3=B5imalust teha head, kuid ei mainita protseduuri olemust ega = v=C3=B5imalikke terviseriske?
  • Kes kontrollib, et naine oleks enne n=C3=B5usoleku andmist saanud = piisavalt teavet?
  • Kas Ravimiametile on viimastel aastatel laekunud kaebusi v=C3=B5i = vihjeid munarakudoonorite v=C3=A4rbamise v=C3=B5i selleks tehtud = reklaamide kohta? Kas j=C3=A4relevalve k=C3=A4igus on tuvastatud = rikkumisi? Kui jah, siis milliseid?

Lugupidamisega
Merilin Lutsar
------=_NextPart_000_0268_01DD4047.4A560530--